NCT06436248 Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer
| NCT ID | NCT06436248 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Ovarian Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 24 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2027-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 24 participants in total. It began in 2024-07-01 with a primary completion date of 2027-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall goal of the Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer (PROMISE) study is to better understand how women may incorporate both polygenic risk score (PRS) and novel early detection strategies in their decisions regarding cancer screening and risk reducing surgery. This study will conduct qualitative interviews to better understand women's attitudes regarding polygenic risk score (PRS) and early detection assays.
Eligibility Criteria
Inclusion Criteria: * Female, age 25 or older (given that women under this age are not generally recommended to receive BRCA1/2 genetic testing) * Completed full sequence or targeted genetic testing with a clinically confirmed BRCA1 or BRCA2 deleterious mutation identified. * English-fluent; the surveys and interviews were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys. Exclusion Criteria: * Previous receipt of any prophylactic oophorectomy * Personal history of ovarian cancer * Major psychiatric illness or cognitive impairment that in the judgment of the study investigators would preclude study participation. * Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.
Contact & Investigator
Susan Domchek, MD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT06436248 clinical trial?
This trial is open to female participants only, aged 25 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06436248 currently recruiting?
Yes, NCT06436248 is actively recruiting participants. Contact the research team at jabrower@pennmedicine.upenn.edu for enrollment information.
Where is the NCT06436248 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT06436248 clinical trial?
NCT06436248 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Susan Domchek, MD at University of Pennsylvania. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.